Friday November 14th was a day of celebration for the Douglas’s Research Center’s Stop-Ad Center. Over 250 persons gathered at the beautiful Espace Rive-Sud golf course in La Prairie for a day of festivities and exchange. Through this annual event, the research team wants to thank the participants who are the backbone of research into this disease.
 

A festive meal gave everyone the opportunity to chat and exchange information. Dr. John Breitner, Dr. Judes Poirier, Dr. Pierre Étienne and Dr. Pedro Rosa-Neto gave an update on the state of research. Just last June, Dr. Poirier and his team discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer’s disease and can delay the onset of the disease by as much as 4 years. This discovery opens new avenues for treatment against this devastating disease.

Thank you to all of you. See you next year!

Stop-AD Center : The mission

The Douglas Institute and McGill University have long recognized an urgent need to develop new strategies to fight the scourge of Alzheimer’s Disease (AD). The faculty of these institutions already possess considerable expertise in the basic and clinical aspects of AD.

They have joined hands to create the Centre for Studies on Prevention of Alzehimer's Disease (StoP-AD Centre) dedicated to the prevention of AD. To bring this expertise together into a coherent whole, the Centre has recruited John Breitner, MD from the University of Washington.
The specific mission of the StoP-AD Centre is the study of Alzheimer’s disease in its pre-symptomatic stages. Alzheimer’s Disease is a chronic illness with a biology that extends at least a decade before any symptoms are evident. By measuring the markers of the disease in these stages, we can test whether some forms of treatment might reverse or slow the progress of pre-symptomatic Alzheimer’s Disease.